自体嵌合抗原受体 T 细胞疗法为各种癌症提供了有希望的治疗结果。然而，其潜力受到独特的供应链挑战的限制，包括动态的患者健康状况和延长的周转时间。这些挑战常常导致错过最佳治疗窗口，阻碍有效提供挽救生命的治疗。本文介绍了 SimPAC（基于模拟的决策支持，用于以患者为中心的自体细胞疗法制造）。 SimPAC 旨在对实时患者健康状况进行建模并将其纳入自体嵌合抗原受体 T 细胞治疗的供应链决策中。 SimPAC 集成了系统动力学和基于代理的仿真技术，有助于根据实时患者健康状况调整制造流程和生产计划。 SimPAC 可以使用参数函数、非参数函数或表格数据对各种患者疾病进展进行建模。此外，SimPAC 还提供简单的配置选项来模拟各种细胞治疗供应链。我们提供两个案例研究来展示 SimPAC 的功能，并强调以患者为中心的制造的好处，包括提高生存率和潜在的经济优势。然而，虽然好处是显着的，但我们的研究还强调了在个性化医疗背景下平衡改善患者结果、经济可行性和伦理考虑的重要性。 SimPAC 可用于探索这种方法在不同治疗环境和供应链配置中的应用。版权所有 © 2024 国际细胞学会

Autologous chimeric antigen receptor T-cell therapy presents promising treatment outcomes for various cancers. However, its potential is restrained by unique supply chain challenges, including dynamic patient health conditions and extended turnaround time. These challenges often lead to missed optimal treatment windows, impeding the effective delivery of life-saving treatments. This article presents SimPAC (simulation-based decision support for Patient-centric manufacturing of autologous cell therapies). SimPAC is designed to model and incorporate real-time patient health conditions into the supply chain decisions of autologous chimeric antigen receptor T-cell therapy. SimPAC integrates system dynamics and agent-based simulation techniques, facilitating the adaptation of manufacturing processes and production schedules based on real-time patient health conditions. SimPAC can model various patient disease progressions using parametric functions, nonparametric functions, or tabular data. Additionally, SimPAC offers easy configuration options to model various cell therapy supply chains. We provide two case studies to demonstrate the capabilities of SimPAC and highlight the benefits of patient-centric manufacturing, including improved survival rates and potential economic advantages. However, while the benefits are significant, our study also emphasizes the importance of balancing improved patient outcomes, economic viability and ethical considerations in the context of personalized medicine. SimPAC can be used to explore applications of this approach to diverse therapeutic contexts and supply chain configurations.Copyright © 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.